Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  International journal of clinical pharmacology and therapeutics

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.5414/CPP48729PMID 20979931
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platinum Resistance: The Role of DNA Repair Pathways

  2008cited by this paper
• Molecular mechanisms of resistance and toxicity associated with platinating agents.

  2007cited by this paper
• Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.

  2007cited by this paper
• Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

  2006cited by this paper
• Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non–Small Cell Lung Cancer Patients

  2005cited by this paper
• ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

  2001cited by this paper
• Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

  2000cited by this paper
• Association of an ERCC1 polymorphism with adult-onset glioma.

  2000cited by this paper
• ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

  1998cited by this paper
• Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties.

  1994cited by this paper

• A Case Study on Complete Pathological Response in Advanced Rectal Cancer Patient with Oxaliplatin-based Chemotherapy without Cumulative Neurotoxicity

  2025cites this paper
• Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: practical biomarkers and robust multiplex models

  2024cites this paper
• Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy

  2023cites this paper
• Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers

  2022cites this paper
• Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark

  2022cites this paper
• Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity.

  2022cites this paper
• Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study

  2021cites this paper
• Predisposing Factors for the Development of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

  2021cites this paper
• Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer

  2019cites this paper
• Potential biomarkers for persistent and neuropathic pain therapy.

  2019cites this paper
• Differential protein expression profiling by iTRAQ‐2D‐LC‐MS/MS of rats treated with oxaliplatin

  2019cites this paper
• GSTP1 as a potential predictive factor for adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy.

  2019cites this paper
• Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral Neuropathy.

  2018cites this paper
• SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand

  2018cites this paper
• Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients

  2018cites this paper
• Predictive biomarkers of chemotherapy-induced peripheral neuropathy: a review.

  2018cites this paper
• Oxaliplatin treatment and peripheral nerve damage in cancer patients: A Polish cohort study

  2018cites this paper
• Energy landscape of a GSTP1 polymorph linked with cytological function decay in response to chemical stressors.

  2017cites this paper
• Association of Voltage-Gated Sodium Channel Genetic Polymorphisms with Oxaliplatin-Induced Chronic Peripheral Neuropathy in South Indian Cancer Patients

  2017cites this paper
• Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy

  2017cites this paper
• Current Pharmacogenetic Approach for Oxaliplatin-induced Peripheral Neuropathy among Patients with Colorectal Cancer: A Systematic Review

  2017cites this paper
• Détection précoce et quantification objective par mesures chronoampérometriques de l’atteinte neurologique périphérique chez des patients recevant une chimiothérapie neurotoxique

  2017cites this paper
• Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy

  2017cites this paper
• Associations analysis of GSTM1, T1 and P1 Ile105Val polymorphisms with carpal tunnel syndrome

  2016cites this paper
• Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).

  2016influential citation
• A genomic case study of mixed fibrolamellar hepatocellular carcinoma

  2016cites this paper
• Chemotherapy‐induced neuropathies—a growing problem for patients and health care providers

  2016cites this paper
• Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis

  2016cites this paper
• Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer

  2016cites this paper
• Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients

  2016cites this paper
• Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.

  2016cites this paper
• Informative gene network for chemotherapy-induced peripheral neuropathy

  2015cites this paper
• Pathogenesis of neurotoxicity and role of signaling in the efficacy of anticancer agents

  2015cites this paper
• Investigation of TNF-alpha gene (G308A) and GSTP1 gene (Ilel05Val) polymorphisms in Turkish patients with retinopathy of prematurity.

  2015cites this paper
• AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin

  2015cites this paper
• Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

  2015cites this paper
• Biotoxicity of Chemotherapy

  2014cites this paper
• Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

  2014cites this paper
• Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study.

  2014cites this paper
• The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.

  2014cites this paper
• Long-term administration and efficacy of oxaliplatin with no neurotoxicity in a patient with rectal cancer: Association between neurotoxicity and the GSTP1 polymorphism

  2014cites this paper
• Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers.

  2014cites this paper
• Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy.

  2014cites this paper
• Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer.

  2013cites this paper
• Neoadjuvant treatment of mid-to-lower rectal cancer with oxaliplatin plus 5-fluorouracil and leucovorin in combination with radiotherapy: a Korean single center phase II study

  2013cites this paper
• Drug-induced neuropathies.

  2013cites this paper
• Investigating the genetics and pharmacogenetics of bowel cancer

  2013cites this paper
• Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer

  2013cites this paper
• Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis

  2013influential citation
• Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action

  2013cites this paper
• Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.

  2012cites this paper
• Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice

  2012cites this paper
• 2 Predictors of Chemotherapy-Induced Peripheral Neuropathy

  2012cites this paper
• Personalized Cancer Medicine

  2012cites this paper
• Predictors of Chemotherapy-Induced Peripheral Neuropathy

  2012cites this paper
• Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.

  2012cites this paper
• Pharmacogenomics and metastatic colorectal cancer: Current knowledge and perspectives

  2012cites this paper
• Toxic neuropathy.

  2011cites this paper
• Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.

  2011cites this paper
• Prediction of response to promising rst-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: Practical biomarkers and robust multiplex models

  year unknowncites this paper
• Practical biomarkers and robust multiplex models for the prediction of response to the promising rst-line chemotherapy: A theranostic study in metastatic ovarian cancer patients with residual peritoneal tumors

  year unknowncites this paper